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was found to be a compound heterozygote for both novel mutations in the ABCA3 gene.
ABCA3 deficiency should be considered in mature babies who develop severe respiratory distress syndrome.
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Respiratory distress syndrome (RDS) is due to deficiency of surfac-
tant and commonly occurs in preterm babies (Avery, 2000). In term
babies this condition can also occur and may be due to abnormalities
of surfactant production.
In addition to surfactant protein-B deficiency (SFTPB), protein-C de-
ficiency (SFTPC) and the gene encoding thyroid transcription factor-1
(NKX2-1) mutations, inherited severe neonatal respiratory distress has
recently been attributed to mutations in the ATP-binding cassette A3
transporter (ABCA3) gene (Brasch et al., 2006; Bullard et al., 2005;
Cutz et al., 2000; Hamvas et al., 2013; Shulenin et al., 2004). ABCA3 pro-
tein is thought to transport lipids into the lamellar bodies (LB), where
the components of mature pulmonary surfactant are assembled before
being secreted into the alveolar airspaces (Ban et al., 2007; Nagata
et al., 2004).
The clinical spectrum and severity of lung disease caused by ABCA3
deficiency is variable, ranging from fulminant neonatal respiratory fail-
ure resulting in death during the first days or months of life or later-
onset interstitial lung disease (Bullard et al., 2005; Doan et al., 2008;
Shulenin et al., 2004; Young et al., 2008)., lamellar bodies; SFTPB, surfac-
hyroid transcription factor-1;
ed tomography; BAL, broncho-
nitis; NBD, nucleotide binding
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l., Novel ABCA3mutations asGenetic testing for mutations in ABCA3 may obviate the need for
lung biopsy in some patients. Approximately 150 mutations in ABCA3
have been reported to date (Gower et al., 2010; Park et al., 2010;
Shulenin et al., 2004; Whitsett et al., 2010).
In this report, we present a newborn that developed immediate re-
spiratory distress and was discovered to be a compound heterozygote
for two novel ABCA3 gene mutations.
2. Patients and methods
2.1. Patients
A 2.41 kg term female infant was born at 37 weeks gestation, via a
spontaneous vaginal delivery, to healthy and non-consanguineous par-
ents. Therewas no family history of birth defects,mental retardation, in-
fant deaths or metabolic disorders.
Her mother was a primigravida. Pregnancy, labor and delivery were
uncomplicated. No meconiumwas noted at birth and there was no his-
tory of perinatal asphyxia, birth traumaor perinatal infection risk.With-
in four hours from birth, she developed severe respiratory distress.
White cell count and C-reactive protein concentration had fallen to
within the normal range. Initial chest radiograph showed diffuse bilat-
eral interstitial infiltrates, consistent with RDS (Fig. 1). An echocardio-
gram revealed no structural or functional heart abnormalities and
excluded pulmonary hypertension.
The newborn was treated with an empiric course of antibiotics and
started nasal continuous positive airway pressure. On day 4 of life inva-
sive ventilation with high fraction of inspired oxygen and mean airway
pressures to maintain adequate oxygenation was started. Natural por-
cine surfactant (Curosurf®) was administered on day 13, 15, 18 anda cause of respiratory distress in a term newborn, Gene (2013), http://
Fig. 1. Chest radiograph at day 4 of life.
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requirements and improvement in blood gasses following each dose
of surfactant, but the effects wore off 18 to 24 h after each treatment.
On day 13 of life, a chest radiograph revealed a white-out of both
lung fields. A computed tomography (CT) scan revealed areas of con-
densation predominantly in left lung (Fig. 2). The esophagram revealed
no abnormalities. Cultures of blood, urine and tracheal aspirate were
negative for bacteria (including ureaplasma) and fungus. Cultures for
viral respiratory pathogens were negative.
A bronchoalveolar lavage (BAL) was performed and the cytology,
cultures and polymerase chain reaction of Pneumocystis jirovecii in bron-
choalveolar lavage fluid were normal.
A repeated echocardiogram showed no signs of pulmonary hyper-
tension. An open lung biopsy was performed, but the results did not
reveal an etiology. Microscopic examination of the lung sample showed
interstitial thickening and septal fibrosis, clustered alveolar macro-
phages, uneven aeration, hypereosinophilic degeneration cellularmate-
rial in the air space and focal areas of hemorrhage were also noted
(Fig. 3). Electronmicroscopywas not performed. Based on lung histolo-
gy, desquamative interstitial pneumonitis (DIP) was diagnosed but pul-
monary alveolar proteinosis could not be firmly excluded.
The patient`s condition continued to deteriorate and corti-
costeroids pulse therapy (metilprednisolone: 30 mg/kg/dose) was
continued in 3-day courses on a monthly basis and oral hydroxy-
chloroquine (10 mg/kg/day) have been used but no clinical im-
provement was observed.Fig. 2. CT scan at 1
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Peripheral bloodwas sent for genetic analysis of the gene enconding,
the surfactant-related proteins SP-B, SP-C and ABCA3 (Institute of Labo-
ratory Medicine and Human Genetics, Singen, Germany). No mutations
were detected in the genes for SP-B and SP-C.
Genomic DNA was extracted from EDTA whole blood with the DNA
Midi Kit® (Qiagen, Hilden/Germany) according to the manufacturer's
protocol. Thus, a second purification step with the DNA Mini Kit®
(Qiagen) had to be performed to minimize the amount of phospolipids
that interfere with the DNA sequencing procedure. Each of the 30 cod-
ing exons of the ABCA3 gene was amplified by PCR using exon specific
primers located in the flanking intronic regions and sequenced by direct
sequencing using an ABI Prism 3100 Genetic Analyser® (Applied
Biosystems, Foster City, CA).
ABCA3 gene analysis revealed two undescribed mutations. She is
a compound heterozygote carrier of a leucine798 (CTT) → proline
(CCT)/p.Leu798Prol/L798P exchange and of an arginine1612 (CGG)→
proline (CCG)/p.Arg1612Pro/R1612P substitution encoded by exons
18 and 31 of the ABCA3 gene. One of these mutations was detected in
analysis of the mother's DNA and the other mutation in the father's.
2.3. Phylogenetic analysis
To analyze the evolutionary (phylogenetic) relation between ABCA3
and related proteins from different organisms, the authors have used
the deduced amino acid sequence of ABCA3 (GenBank accession num-
ber NP_001080) to search the sequence data base using BLAST program
(http://www.ncbi.nlm.nih.gov/blast/). Similar proteins were also iden-
tified in other species.
The protein relations from different organisms (human (Homo sapi-
ens), baboon (Papio anubis), horse (Equus caballus), orca (Orcinus orca),
domestic cow (Bos taurus), andmouse (Musmusculus)) were evaluated
using amino acid alignment (Clustal X program) (Thompson et al.,
1997) (Fig. 4).
3. Results
Over the ensuing weeks, the infant's work of breathing increased
significantly and she required increasingly higher levels of supplemen-
tal oxygenation. On 101 days of life, after discussions with parents and
family, intensive care was withdrawn and she died peacefully.
4. Discussion
Mutations in ABCA3 appear to be themost common cause of genetic
surfactant dysfunction in humans (Shulenin et al., 2004; Somaschini3 days of life.
a cause of respiratory distress in a term newborn, Gene (2013), http://
Fig. 3.Histopathology of ABCA3-deficient lung tissue demonstrating interstitial thickening and septal fibrosis (A); clustered alveolarmacrophages (B); collapsed alveoli (C); focal areas of
hemorrhage and hypereosinophilic degeneration material in the air space (D).
3J.-P. Gonçalves et al. / Gene xxx (2013) xxx–xxxet al., 2007). The mutations result in a loss or reduced function of the
ABCA3 protein, and are inherited in an autosomal recessive manner. It
is assumed that homozygosity or compound heterozygosity for ABCA3
mutations causes fatal respiratory distress syndrome in newborns
(Shulenin et al., 2004). The severe neonatal form of the disease is
thought to result from a lack of functional surfactant. Disease caused
by ABCA3 mutations varies in its presentation depending upon the de-
gree of ABCA3 dysfunction. Fatal surfactant deficiency due to ABCA3mu-
tationmay be classified into two categories, type I and type II, abnormalFig. 4. Degree of conservation of residues involved
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dx.doi.org/10.1016/j.gene.2013.11.015intracellular trafficking and decreased ATP hydrolysis activity. These
distinct pathophysiologies may be useful in assessing both the severity
and effective therapy for surfactant deficiency (Matsumura et al.,
2006). Approximately 150 different variants have been reported in the
literature, most leading to severe neonatal lung disease (Whitsett
et al., 2010). While most mutations in ABCA3 are unique, some have
been identified among multiple symptomatic individuals including
E292V(Bush, 2004; Garmany et al., 2008). The carrier rate of ABCA3mu-
tation in European-decent individuals was reported to be 3.6% and it isin missense mutations in the ABCA3 protein.
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this population (Wambach et al., 2012). Our case report was unfortu-
nate tohave inherited twodifferentmutations fromher parents, leading
most likely to abnormal surfactant function and clinical features of se-
vere RDS. The histolopathologic findings in the lung biopsy revealed a
non-specific interstitial pneumonia and features of chronic pneumonitis
of infancy.
To our knowledge, both mutations have not been published before
and are not found among variants reported in NHLBI GO Exome Se-
quencing Project (ESP) (Tennessen et al., 2012).
Experimental approaches to analyze protein expression, location
and function are highly laborious and were not performed. The com-
putational analysis is less informative than direct experimental evi-
dence but do not involve additional labor, cost and can be applied to
any gene. To infer the causality and functional significance of these
mutations computational prediction algorithms were performed
(PolyPhen-2) (Sunyaev, 2012). In this case report PolyPhen-2 predicts
that L798P is probably damaging (high confidence supposed to affect
protein function and structure) and R1612P is benign (most likely lack-
ing any phenotypic effect). It appears that L798P is located in a nucleo-
tide binding domain (NBD1), while R1612P in NBD2.
A variant is more likely to be a deleterious mutation if it affects an
amino acid residue that is conserved across species. The authors there-
fore aligned the human, mouse, domestic cow, baboon, horse, and orca
amino acid sequences of ABCA3. The L798Pmutations occur in a residue
in the ATP-binding domain that is highly conserved, and it almost cer-
tainly disrupts the function of the protein.
The clinical phenotype and genetic findings support the notion that
these mutations were deleterious rather than neutral variants.
Analysis of the genes involved in surfactant dysfunction disorders is
recommended because it is noninvasive and a positive molecular diag-
nosis may obviate the need for lung biopsy. Genetic analysis in this
casewas of significant benefit to the patient's family because it provided
an explanation for the child's severe lung disease andwas important for
proper counseling regarding prognosis.
To date, information of the treatment of this disease in newborns
and infants are still scarce. Treatment modalities are extrapolated
from adult practice or experience in the treatment of other investigated
lung diseases. Although there is no clear evidence about their beneficial
effect, systemic corticosteroids and hydroxychloroquine are widely
used for interstitial lung disease (Vece and Fan, 2011). In a few cases
with ABCA3mutations, these drugs have been shown to have beneficial
effects (Hayes et al., 2012; Yokota et al., 2008).
Lung transplantation is the only definitive treatment option for
patients with severe disease due to ABCA3 deficiency. Although
lung transplantation is not readily available and highly problematic
in very young infants this treatment carries similar survival rates to
older children with lung transplantation (Elizur et al., 2009). The
majority of infants with severe dysfunction of ABCA3 and without
lung transplantation do not survive beyond 3 to 6 months of life
(Hayes et al., 2012).Disclosure statement
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